Used primarily in the development of targeted drug delivery systems, this thalidomide derivative acts as a linker molecule in bioconjugation strategies. Its structure, incorporating a thalidomide moiety, piperazine ring, PEG spacer, and terminal amino group, allows for the attachment of therapeutic agents to targeting moieties, enhancing the specificity and efficacy of treatments, particularly in cancer therapy and autoimmune diseases. The piperazine ring provides flexibility and stability, while the PEG spacer improves solubility and reduces immunogenicity. The amino group facilitates easy conjugation with various functional groups, making it versatile in the synthesis of prodrugs and antibody-drug conjugates. Its application is crucial in creating more effective and safer pharmaceutical formulations.